Dianthus Therapeutics Overview
Dianthus Therapeutics Target Price
Analysts' 12-month price predictions for DNTH.
Get informed when a big investor buys or sells
+ FollowShare Price
$101.28
Average Target Price
$118.75
17.2% upside
17.2% upside4 analysts in the last 4 months
High: $132 | Low: $98
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-06-10 | Jefferies | $132 | 30.3% upside |  |
| 2026-05-11 | Evercore ISIGavin Clark-Gartner | $120 | 18.5% upside | |
| 2026-05-06 | Raymond James | $125 | 23.4% upside | |
| 2026-04-08 | Wolfe ResearchAndy Chen | $98 |  3.2% downside | |
| 2026-03-09 | UBSMaury Raycroft | $98 | 3.2% downside | |
| 2026-03-09 | JefferiesMaury Raycroft | $98 | 3.2% downside | |
| 2026-03-09 | Robert W. Baird | $132 | 30.3% upside | |
| 2026-03-09 | H.C. WainwrightSwayampakula Ramakanth | $130 | 28.4% upside | |
| 2026-03-09 | OppenheimerTrevor Allred | $145 | 43.2% upside | |
| 2026-03-09 | Stifel NicolausAlex Thompson | $120 | 18.5% upside | |
| 2026-03-09 | Truist Financial | $110 | 8.6% upside | |
| 2026-02-11 | Wedbush | $55 | 45.7% downside | |
| 2026-01-29 | UBS | $125 | 23.4% upside | |
| 2026-01-08 | Truist Financial | $63 | 37.8% downside | |
| 2025-11-06 | OppenheimerTrevor Allred | $62 | 38.8% downside | |
| 2025-10-14 | Truist FinancialDanielle Brill | $56 | 44.7% downside | |
| 2025-09-08 | GuggenheimYatin Suneja | $100 | 1.3% downside | |
| 2025-09-08 | JefferiesMaury Raycroft | $51 | 49.6% downside | |
| 2024-11-11 | OppenheimerLeland Gershell | $52 | 48.7% downside | |
| 2024-04-18 | Raymond JamesSteven Seedhouse | $51 | 49.6% downside | |